Larimar Therapeutics, Inc. Common Stock (LRMR) Stock Price
LRMRStock
$4.16+3.58%52W
Market Cap$432.15M
P/E—
PEG Ratio—
Div yield—
Beta0.69
LRMR Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)26.04%
Price vs S&P 500 (4W)2.69%
VGM Score60.13
LRMR Earnings Surprise History
Q2 25-0.41est. -0.49
Q3 25-0.61est. -0.42
Q4 25-0.73est. -0.55
Q1 26-0.31est. -0.59
Q2 26-0.30est. -0.38
LRMR Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.47
4.44
4.44
4.41
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LRMRLarimar Therapeutics, Inc. Common Stock | — | — | B | $4.16 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Larimar Therapeutics, Inc. Common Stock
Larimar Therapeutics is a clinical-stage biotechnology company developing treatments for rare genetic diseases using its proprietary cell-penetrating peptide technology platform. Its lead candidate, CTI-1601, is designed to deliver a critical missing protein directly to the mitochondria of patients with Friedreich's ataxia via subcutaneous injection. The company is advancing a novel treatment approach to address a significant unmet medical need in the rare disease space.